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Abstract
Cutaneous leishmaniasis is one of the most frequent skin diseases
occurring after travelling in endemic areas. Optimal management
requires identiﬁcation of the species of Leishmania involved. In this
study we aimed to evaluate the use of molecular diagnosis as
routine, in comparison with direct examination and culture. Thirty
positive diagnoses were carried out between 2007 and 2013.
Classical PCR enabled 11 positive cases to be identiﬁed that were
found to be negative by conventional methods. Sequencing led to
the identiﬁcation of eight different species. Routine use of PCR and
sequencing appears very efﬁcient in the management of cutaneous
leishmaniasis.
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Introduction
Dermatological complaints are the third reason for travellers
to seek medical consultations. Cutaneous leishmaniasis (CL) is
one of the ten most frequent skin diseases occurring after
travelling [1] in North Africa, and Central and South America
[2]. In recent years there has been an increase in the incidence
of CL due to a greater number of international travellers,
adventure holidays, migrations and military operations in
endemic areas [3]. Because of the wide range of destinations
there is a great variety in Leishmania species responsible for
cutaneous lesions in travellers. In the Old World (OW), CL is
mainly due to L. tropica, L. major and L. infantum, while
L. guyanensis, L. braziliensis, L. mexicana and L. panamensis are
found in the New World (NW). The physical aspects of the
lesions can rarely allow the identiﬁcation of the species
involved, whereas each species has its own prognosis and
treatment. Thus recent guidelines have been published for the
management of CL that consider the lesion, the patient’s status
and the infecting species [4,5]. In this context, molecular tools
could represent an interesting alternative to improve the
diagnosis and management of CL.
Since 2007, in the Parasitology–Mycology Department of
the Toulouse University Hospital (France), diagnosis of CL has
been carried out by the combination of microscopic exami-
nation after May–Gr€unwald Giemsa staining, culture on
Novy-MacNeal-Nicolle medium and molecular techniques.
The molecular biology tools consist of a classical PCR that
targets a conserved region (18S gene) [6] and for each positive
sample, the species is then identiﬁed by sequencing a part of
the cytochrome b gene as described by Foulet et al. [7]. If
required, the PCR and sequencing are performed twice and
once a week, respectively. In order to assess the value of
molecular biology in comparison with conventional methods
(microscopic examination and culture), we collected retro-
spectively all CL cases diagnosed in the department from
January 2007 to July 2013.
During this period, of the 133 patients for whom physicians
suspected CL, 17 samples were positive after microscopic
examination and/or culture, while 30 were positive using PCR
(Table 1). All positive samples found using conventional
methods were positive after PCR analysis. Two samples were
positive after culture whereas they were negative on micro-
scopic examination, and conversely, four samples had a
negative culture while they were positive by microscopy.
The PCR enabled the identiﬁcation of 11 (39%) positive cases
that were found to be negative by conventional methods. Our
study showed that diagnosis of CL by PCR was more sensitive
than conventional techniques and faster than culture in routine
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diagnosis as shown in previous studies [8–11]. More precisely,
our data showed that only 54% (15/28) and 47% (7/15) of our
samples were positive when assessed by microscopy and
culture, respectively. Independently of the parasite load or
species involved, the success of microscopy and culture may
depend on the quality of the cutaneous sample. In our centre,
travellers were usually cared for by non-dermatologist physi-
cians who most often obtained a skin sample by simply
scraping rather than a true biopsy, which may explain, in part,
the low sensitivity of our conventional diagnosis.
Among the 30 positive samples sequenced, 29 identiﬁca-
tions were carried out and eight different species were
identiﬁed (Table 2). Only one sequencing failed due to a low
amount of DNA. The two main species found were L. guyan-
ensis from South America and L. major from North Africa.
Although these two species represented 76% (22/29) of
identiﬁed Leishmania, the diversity of species found showed
that sequencing produced clinically relevant information.
Among the eight cases of CL emanating from the OW, six
were infected by L. major, one by L. tropica and one by
L. aetiopica. Although the classical appearance of lesions caused
by L. major or L. tropica allows these two species to in principle
be distinguished, in practice it is not so easy. The need for an
anti-leishmanial therapy is not systematic for L. major as lesions
cure spontaneously within a few months. For L. tropica, lesions
can evolve over 1 or 2 years and thus the management usually
requires speciﬁc therapy [5]. Even if it is exceptional in
travellers, CL caused by L. aethiopica can lead to diffuse CL in
anergic patients. Among the 19 patients who travelled in the
NW, 16 were infected by L. guyanensis, one by L. braziliensis,
one by L. panamensis and one by L. naifﬁ. Seventeen patients
were infected in French Guiana and 11 of them were military
personnel who were infected during the same mission in a
tropical forest. Interestingly, among this cluster of 11 patients,
sequencing allowed one patient to be detected who was
infected by L. braziliensis. L. guyanensis and L. braziliensis are
clinically similar but may evolve differently. L. guyanensis causes
almost exclusively cutaneous lesions that can be treated by a
short course of pentamidine [4]. L. braziliensis, as L. panamen-
sis, can lead to muco-cutaneous leishmaniasis, which is
life-threatening and requires injections of pentavalent anti-
mony for 20 days or liposomal amphotericin B if the ﬁrst line
of treatment fails [4].
Of the 30 positive samples, two patients were infected by
L. infantum. An epidemiological investigation revealed that
neither of them had travelled outside France for several years.
The ﬁrst case was a young Tunisian-born woman who did not
return there for 7 years. The second case was a 50-year-old
male native of the French West Indies (Guadeloupe) who also
did not travel outside France for 3 years. The two patients had
no clinical or biological evidence of visceral leishmaniasis. Even
if it is not so common, it is well-known that L. infantum can also
be responsible for skin lesions without systemic involvement.
In south-eastern France, where L. infantum is the only endemic
species, 39 cases of autochthonous CL have been reported
between 1999 and 2012 [12], implying that CL must be
considered in cases of chronic wounds. In North Africa and
the Middle East, where L. major and L. tropica are the main
species found in CL, CL may also be due to L. infantum.
Considering all these clinical and therapeutic characteristics,
the precise identiﬁcation of species of involved Leishmania is
important. Until now, the ‘gold standard’ to identify Leishmania
was the isoenzyme characterization, described by Rioux et al.
[13]. Nevertheless, this technique takes a long time due to the
TABLE 1. Results of culture and microscopic examination of
all 30 PCR-positive samples
Positive conventional techniques 17 (61%)
DE (+)/C (+) 5
DE (+)/C () 4
DE ()/C (+) 2
DE (+)/C (NP) 6
Negative conventional techniques 11 (39%)
NP conventional techniques 2a
Total 30
DE, direct examination; C, culture; NP, not performed; (+), positive; (), negative.
aSamples collected on a swab.
TABLE 2. Epidemiology and species identiﬁcation of the 30
PCR-positive samples
Sex Age (years) Country Results of sequencing
1 M 13 Tunisia L. major
2 M 57 Tunisia L. major
3 M 65 Tunisia Unknown
4 F 8 Algeria L. major
5 F 81 Algeria L. major
6 M 16 Morocco L. major
7 M 55 Morocco L. major
8 M 2 Ethiopia L. aethiopica
9 M 72 North Africaa L. tropica
10 M 59 French Guiana L. guyanensis
11 M 19 French Guiana L. guyanensis
12 M 26 French Guiana L. guyanensis
13 M 27 French Guiana L. guyanensis
14 M 21 French Guiana L. guyanensis
15 M 21 French Guiana L. guyanensis
16 M 22 French Guiana L. guyanensis
17 M 20 French Guiana L. guyanensis
18 M 20 French Guiana L. guyanensis
19 M 20 French Guiana L. guyanensis
20 M 19 French Guiana L. guyanensis
21 M 23 French Guiana L. guyanensis
22 M 21 French Guiana L. guyanensis
23 M 26 French Guiana L. guyanensis
24 M 25 French Guiana L. guyanensis
25 M 34 French Guiana L. naifﬁ
26 M 22 French Guiana L. brasiliensis
27 M 29 Peru L. guyanensis
28 F 21 Costa Rica L. panamensis
29 F 23 No travelb L. infantum
30 M 51 No travelc L. infantum
M, male; F, female.
aTravel in North Africa.
bNative of Tunisia.
cNative of French Indies (Guadeloupe).
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need to culture the parasites and is available only in very few
reference centres. Identiﬁcation of species by sequencing has
several advantages: achievable without culture, rapid execution
and the availability of the technology now in many referral
hospitals.
In conclusion, microscopic examination remains useful
because it allows a quick and easy diagnosis in about 50% of
cases of CL. Apart from the interest related to the isolation of
strains, culture is not strictly speaking pertinent for diagnosis.
In contrast, PCR and sequencing appear very relevant for the
diagnosis and the management of CL, and for epidemiological
surveillance.
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